Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Oncology Biomarker Market Status and Forecast (2017-2028)
  • 1.3.2 Global Oncology Biomarker Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Oncology Biomarker Supply by Company

• 2.1 Global Oncology Biomarker Sales Value by Company
• 2.2 Oncology Biomarker Sales Area of Main Manufacturers
• 2.3 Trend of Concentration Rate

3 Global and Regional Oncology Biomarker Market Status by Type

• 3.1 Oncology Biomarker Type Introduction
  • 3.1.1 Lung Cancer
  • 3.1.2 Breast Cancer
  • 3.1.3 Colorectal Cancer
  • 3.1.4 Prostate Cancer
  • 3.1.5 Stomach Cancer
  • 3.1.6 Others
• 3.2 Global Oncology Biomarker Market by Type
• 3.3 North America: by Type
• 3.4 Europe: by Type
• 3.5 Asia Pacific: by Type
• 3.6 Central & South America: by Type
• 3.7 Middle East & Africa: by Type

4 Global and Regional Oncology Biomarker Market Status by Application

• 4.1 Oncology Biomarker Segment by Application
  • 4.1.1 Diagnostics
  • 4.1.2 Drug Discovery And Development
  • 4.1.3 Prognostics
  • 4.1.4 Risk Assessment
  • 4.1.5 Others
• 4.2 Global Oncology Biomarker Market by Application
• 4.3 North America: by Application
• 4.4 Europe: by Application
• 4.5 Asia Pacific: by Application
• 4.6 Central & South America: by Application
• 4.7 Middle East & Africa: by Application

5 Global Oncology Biomarker Market Status by Region

• 5.1 Global Oncology Biomarker Market by Region
• 5.2 North America Oncology Biomarker Market Status
• 5.3 Europe Oncology Biomarker Market Status
• 5.4 Asia Pacific Oncology Biomarker Market Status
• 5.5 Central & South America Oncology Biomarker Market Status
• 5.6 Middle East & Africa Oncology Biomarker Market Status

6 North America Oncology Biomarker Market Status

• 6.1 North America Oncology Biomarker Market by Country
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Oncology Biomarker Market Status

• 7.1 Europe Oncology Biomarker Market by Country
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Oncology Biomarker Market Status

• 8.1 Asia Pacific Oncology Biomarker Market by Country
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Oncology Biomarker Market Status

• 9.1 Central & South America Oncology Biomarker Market by Country
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Oncology Biomarker Market Status

• 10.1 Middle East & Africa Oncology Biomarker Market by Country
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Major Downstream Customers Analysis

• 11.1 Customer One Analysis
• 11.2 Customer Two Analysis
• 11.3 Customer Three Analysis
• 11.4 Customer Four Analysis

12 Global Oncology Biomarker Market Forecast by Type and by Application

• 12.1 Global Oncology Biomarker Sales Value Forecast (2023-2028)
• 12.2 Global Oncology Biomarker Forecast by Type
• 12.3 Global Oncology Biomarker Forecast by Application

13 Global Oncology Biomarker Market Forecast by Region/Country

• 13.1 Global Oncology Biomarker Market Forecast by Region (2023-2028)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Qiagen N.V.
  • 14.1.1 Company Information
  • 14.1.2 Oncology Biomarker Product Introduction
  • 14.1.3 Qiagen N.V. Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.1.4 SWOT Analysis
• 14.2 Pfizer
  • 14.2.1 Company Information
  • 14.2.2 Oncology Biomarker Product Introduction
  • 14.2.3 Pfizer Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.2.4 SWOT Analysis
• 14.3 Novartis AG
  • 14.3.1 Company Information
  • 14.3.2 Oncology Biomarker Product Introduction
  • 14.3.3 Novartis AG Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.3.4 SWOT Analysis
• 14.4 Merck & Co.
  • 14.4.1 Company Information
  • 14.4.2 Oncology Biomarker Product Introduction
  • 14.4.3 Merck & Co. Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.4.4 SWOT Analysis
• 14.5 GlaxoSmithKline plc
  • 14.5.1 Company Information
  • 14.5.2 Oncology Biomarker Product Introduction
  • 14.5.3 GlaxoSmithKline plc Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.5.4 SWOT Analysis
• 14.6 Genomic Health
  • 14.6.1 Company Information
  • 14.6.2 Oncology Biomarker Product Introduction
  • 14.6.3 Genomic Health Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.6.4 SWOT Analysis
• 14.7 F.Hoffmann-La Roche Ltd.
  • 14.7.1 Company Information
  • 14.7.2 Oncology Biomarker Product Introduction
  • 14.7.3 F.Hoffmann-La Roche Ltd. Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.7.4 SWOT Analysis
• 14.8 Eli Lilly and Company
  • 14.8.1 Company Information
  • 14.8.2 Oncology Biomarker Product Introduction
  • 14.8.3 Eli Lilly and Company Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.8.4 SWOT Analysis
• 14.9 Bristol-Myers Squibb
  • 14.9.1 Company Information
  • 14.9.2 Oncology Biomarker Product Introduction
  • 14.9.3 Bristol-Myers Squibb Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.9.4 SWOT Analysis
• 14.10 Abbott Laboratories
  • 14.10.1 Company Information
  • 14.10.2 Oncology Biomarker Product Introduction
  • 14.10.3 Abbott Laboratories Oncology Biomarker Sales Value, Gross Margin and Global Share (2020-2022)
  • 14.10.4 SWOT Analysis

15 Conclusion

16 Methodology

This report provides a comprehensive analysis of current global Oncology Biomarker market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Oncology Biomarker industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

According to this survey, the global Oncology Biomarker market is estimated at $ million in 2021, and projected to grow at a CAGR of % to $ million by 2028.

Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Oncology Biomarker Market Opportunities and Forecast 2023-2028 report makes a brilliant attempt to unveil key opportunities available in the global Oncology Biomarker market under the Covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

The Global Oncology Biomarker Market has been exhibited in detail in the following chapters
Chapter 1 displays the basic product introduction and market overview.
Chapter 2 provides the competition landscape of global Oncology Biomarker industry.
Chapter 3 provides the market analysis by type and by region
Chapter 4 provides the market analysis by application and by region
Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
Chapter 12 provides the market forecast by type and by application
Chapter 13 provides the market forecast by region
Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
Chapter 15 conclusions

Segmented by Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others

Segmented by Application
Diagnostics
Drug Discovery And Development
Prognostics
Risk Assessment
Others

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
Qiagen N.V.
Pfizer
Novartis AG
Merck & Co.
GlaxoSmithKline plc
Genomic Health
F.Hoffmann-La Roche Ltd.
Eli Lilly and Company
Bristol-Myers Squibb
Abbott Laboratories